AbCellera Biologics (ABCL) Net Margin (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Net Margin came in at 519.12% in Q1 2026, up 55812.0% YoY from N/an in Q1 2025, and down 2503.04% on a QoQ basis from 19.94% in Q4 2025.
Powered by 
Analysis
AbCellera Biologics (ABCL) Net Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Net Margin data on file, last reported at 519.12% in Q1 2026.
- Quarterly Net Margin rose 55812.0% year-over-year to 519.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 181.75% (up 54448.0% YoY) and the FY2025 annual result came in at 194.88%, up 36995.0% from the prior year.
- Net Margin eased to 519.12% in Q1 2026, from 19.94% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 53.25% in Q1 2022 to a low of 1077.24% in Q1 2025.
- A 5-year average of 381.55% and a median of 407.98% in 2024 frame the typical range for Net Margin.
- The widest YoY moves for Net Margin: up 65748 bps in 2025, down 66926 bps in 2025.
- Tracing ABCL's Net Margin over 5 years: stood at 138.75% in 2022, then plunged by 270 bps to 513.67% in 2023, then plunged by 32 bps to 677.43% in 2024, then surged by 97 bps to 19.94% in 2025, then tumbled by 2503 bps to 519.12% in 2026.
- The last three Net Margin figures came in at 519.12% (Q1 2026), 19.94% (Q4 2025), and 637.84% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -1,368.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,368.57% |
| Mar 31, 2026 | -519.12% |
| Dec 31, 2025 | -19.94% |
| Sep 30, 2025 | -637.84% |
| Jun 30, 2025 | -203.27% |
| Mar 31, 2025 | -1,077.24% |
| Dec 31, 2024 | -677.43% |
| Sep 30, 2024 | -785.42% |
| Jun 30, 2024 | -504.30% |
| Mar 31, 2024 | -407.98% |
| Dec 31, 2023 | -513.67% |
| Sep 30, 2023 | -433.55% |
| Jun 30, 2023 | -303.58% |
| Mar 31, 2023 | -328.99% |
| Dec 31, 2022 | -138.75% |
| Sep 30, 2022 | 26.26% |
| Jun 30, 2022 | -14.78% |
| Mar 31, 2022 | 53.25% |
| Dec 31, 2021 | 43.03% |
| Sep 30, 2021 | -388.16% |